Regulation as an Enabler of Innovation: A Regional Perspective

Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.

How to use the procedure for medicines licensing applications.

How the MHRA makes decisions on what is a medicinal product (borderline products).

Summary of the latest safety advice for medicines and medical device users

Information for patients, public and healthcare professionals

Relonchem Ltd has informed the MHRA that duplicate GTIN numbers have been assigned to certain Losartan potassium/Hydrochlorothiazide coated tablets in error and a duplicate EAN number has been assigned to certain Risperidone tablets in error.